APA (7th ed.) Citation

Scalambra, L., Ruzzi, F., Pittino, O. M., Semprini, M. S., Cappello, C., Angelicola, S., . . . Lollini, P. (2025). Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma. Journal of Translational Medicine, 23(1), 1. https://doi.org/10.1186/s12967-025-06126-w

Chicago Style (17th ed.) Citation

Scalambra, Laura, et al. "Targeting PCSK9, Through an Innovative CVLP-based Vaccine, Enhanced the Therapeutic Activity of a CVLP-HER2 Vaccine in a Preclinical Model of HER2-positive Mammary Carcinoma." Journal of Translational Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12967-025-06126-w.

MLA (9th ed.) Citation

Scalambra, Laura, et al. "Targeting PCSK9, Through an Innovative CVLP-based Vaccine, Enhanced the Therapeutic Activity of a CVLP-HER2 Vaccine in a Preclinical Model of HER2-positive Mammary Carcinoma." Journal of Translational Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12967-025-06126-w.